ArticleBMC complementary medicine and therapies2025
Evaluation of the antiproliferative, cytotoxic and phytochemical properties of Zimbabwean medicinal plants used in cancer treatment.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Traditional and modern practitioners' perceptions on traditional medicine use in reproductive health among the Khoisan of Zimbabwe.Frontiers in reproductive health · 2026Article
- From tradition to evidence: medicinal plants used for childhood diseases in the Ehlanzeni District, Mpumalanga Province, South Africa.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCancer cases have been on the rise globally and several treatment strategies have been developed but mortality rates remain high. Zimbabwe, like many other countries, has also experienced a surge in cancer cases. In Zimbabwe, medicinal plants have been widely used to treat cancer for centuries. However, there has been limited research on the effectiveness, safety, and chemical composition of these plants. The current study assessed antiproliferative, cytotoxic and phytochemical properties of selected Zimbabwean medicinal plants.
methodCytotoxic activity of Agelenthus pungu, Carissa edulis, Dombeya rotundifolia, Flacourtia indica, Lannea discolor, Leonotis ocymifolia, Leucas martinicensis, Plicosepalus kalachariensis, Pseudolachnostylis maproneifolia, Solanum incanum, Strychnos cocculoides, Strychnos spinosa and Viscum verrucosum extracts were evaluated on normal murine peritoneal cells and sheep erythrocytes while antiproliferative activity was assessed on Jurkat T and HL60 cell lines. Cell viability was determined using the trypan blue exclusion and sulforhodamine B assay. Additionally, the effect of reduced glutathione on cytotoxic extracts was examined. The phytochemicals of the methanolic extracts were qualitatively determined using standard methods.
resultsAgelenthus pungu, Carissa edulis, Flacourtia indica, Strychnos cocculoides, Strychnos spinosa and Viscum verrucosum were cytotoxic to normal murine peritoneal cells. Flacourtia indica and Viscum verruscosum caused haemolysis of sheep erythrocytes at a concentration of 250 µg/mL for both plant extracts and 125 µg/mL for Viscum verrucosum. Cell viability increased on addition of 25 µg/mL of reduced glutathione to the extracts considered the most cytotoxic extracts, Agelenthus pungu and Viscum verrucosum. Agelenthus pungu, Carissa edulis, Leonotis ocymifolia, Leucas martinicensis and Viscum verrucosum significantly inhibited Jurkat T and HL60 cell proliferation. Viscum verrucosum was the most potent with the lowest half-maximum inhibitory concentration (IC
conclusionThis study demonstrates that Agelenthus pungu, Carissa edulis, Leonotis ocymifolia, Leucas martinicensis and Viscum verrucosum have antiproliferative activity against Jurkat T and HL60 cell lines. Viscum verrucosum was the most potent. These findings emphasise the importance of medicinal plants as well as their potential use as sources of novel compounds in anticancer drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.